Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Liabilities and Shareholders Equity (2018 - 2025)

Neurogene (NGNE) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $297.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Liabilities and Shareholders Equity rose 65.34% year-over-year to $297.3 million, compared with a TTM value of $948.3 million through Sep 2025, up 24.62%, and an annual FY2024 reading of $335.7 million, changed N/A over the prior year.
  • Liabilities and Shareholders Equity was $297.3 million for Q2 2025 at Neurogene, down from $315.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $335.7 million in Q4 2024 and bottomed at $164.1 million in Q3 2024.